

wherein

 R^1 represents C_{1-12} alkyl, $-(CH_2)_a$ -aryl, or $(CH_2)_a$ Het¹ (all of which are optionally substituted by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

a represents 0, 1, 2, 3, or 4;

Het¹ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

R^{5a} and R^{5b} independently represent H or C₁₋₃ alkyl;

 R^2 and R^3 independently represent H, C_{1-4} alkyl (optionally substituted with one or more nitro or cyano groups), OR^7 , $N(R^{7a})R^{7b}$, $OC(O)R^8$ or together form -O-(CH₂)₂-O-, - (CH₂)₃-, -(CH₂)₄- or -(CH₂)₅-;

 R^7 and R^8 independently represent H, C_{1-6} alkyl or - $(CH_2)_b$ -aryl (which latter two groups are optionally substituted by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

R^{7a} and R^{7b} independently represent H or C₁₋₆ alkyl;

b represents 0, 1, 2, 3 or 4;

R⁴ represents H or C₁₋₆ alkyl;

D represents H, -OH, or -(CH_2)_cN(R^{10})(R^{11});

c represents 0, 1, 2, 3 or 4;

 R^{10} represents H, C_{1-6} alkyl, $-(CH_2)_d$ -aryl, $-C(NH)NH_2$, $-S(O)_2R^{13}$, $-_eN(R^{14})(R^{15})$, $-C(O)R^{16}$ or $-C(O)OR^{17}$;

e represents 1 or 2;

 R^{11} represents H, C_{1-6} alkyl, $-C(O)R^{18}$ or $-(CH_2)_f$ -aryl (which latter group is optionally substituted by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

 R^{14} , R^{15} , R^{16} , R^{17} and R^{18} independently represent H, C_{1-6} alkyl, Het^2 or $-(CH_2)_g$ -aryl (which latter three groups are optionally substituted by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

 R^{13} represents C_{1-6} alkyl, aryl or - $(CH_2)_h$ -aryl (all of which are all optionally substituted by one or more substituents chosen from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

d, f, g and h independently represent 0, 1, 2, 3 or 4;

Het² represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

 R^6 represents one or more optional substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl (optionally terminated by -N(H)C(O)OR^{18a}), C_{1-6} alkoxy, -C(O)N(H)R¹⁹, -NHC(O)N(H)R²⁰, -N(H)S(O)₂R²¹ and/or -OS(O)₂R²²;

R¹⁹ and R²⁰ independently represent H or C₁₋₆ alkyl;

R^{18a}, R²¹ and R²² independently represent C₁₋₆ alkyl;

A represents a single bond, C_{1-6} alkylene, $-N(R^{23})(CH_2)_{j^-}$, $-O(CH_2)_{j^-}$ or $-(CH_2)_{J}C(H)(OR^{23})(CH_2)_{k^-}$ (in which latter three groups, the $-(CH_2)_{j^-}$ group is attached to the bispidine nitrogen atom, and which latter four groups are all optionally substituted by one or more OH groups);

B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mN(R^{24})$ -, $(CH_2)_mS(O)_n$ -, $-(CH_2)_mO$ - (in which three latter groups, the $-(CH_2)_m$ - group is attached to the carbon atom bearing D and R⁴), $-C(O)N(R^{24})$ - (in which latter group, the -C(O)- group is attached to the carbon atom bearing D and R⁴), $N(R^{24})C(O)O(CH_2)_m$ - or $-N(R^{24})(CH_2)_m$ - (in which latter two groups, the $N(R^{24})$ group is attached to the carbon atom bearing D and R⁴);

j, k and m independently represent 0, 1, 2, 3 or 4;

n represents 0, 1 or 2;

R²³ represents H, C₁₋₆ alkyl or

R²⁴ represents H or C₁₋₆ alkyl;

 R^{25} represents H, C_{1-6} alkyl, Het^3 or $-(CH_2)_p$ -aryl (which latter two groups are optionally substituted by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

Het³ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

p represents 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt, , N-oxide or quaternary ammonium derivative thereof;

wherein alkyl groups that R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, R⁷, R^{7a}, R^{7b}, R⁸, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R^{18a}, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵ and D may represent, and with which R¹, R⁷, R⁸, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R²⁵ may be substituted; and alkoxy groups and R⁶ may represent, and with which R¹, R⁷, R⁸, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R²⁵ may be substituted, may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched and/or cyclic, and wherein, when there is a sufficient number (i.e. four) of carbon atoms, such alkyl and alkoxy groups may also be part cyclic/acyclic, and wherein such alkyl and alkoxy groups may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen and/or substituted by one or more fluoro groups; and

wherein alkylene groups that A and B may represent, and –(CH₂)- containing groups that R¹, R² and R³ (together), R⁷, R⁸, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R²⁵, A, B and D may include, may be linear or, when there is a sufficient number (i.e. two) of carbon atoms, be branched, and wherein such alkylene groups and –(CH₂)- containing chains may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen;

provided that:

- (a) when D represents either H or -OH, and R^{5a} and R^{5b} both represent H, then at least one of R² and R³ represents OR⁷, OC(O)R⁸ or C₁₋₄ alkyl, which alkyl group is substituted with one or more nitro or cyano groups; and
 - (b) when D represents -OH or -(CH₂)_cN(R¹⁰)R¹¹ in which c represents 0, then:-

BJORE et al Serial No. 09/623,709

- (i) A does not represent $-N(R^{23})(CH_2)_{j^-}$, $-O(CH_2)_{j^-}$ or $-CH_2)_JC(H)(OR^{23})(CH_2)_{k^-}$ (in which k is 0); and/or
- (ii) m does not represent 0 when B represents -(CH₂)_mN(R²⁴)-, -(CH₂)_mS(O)_n- or -(CH₂)_mO-.
- 2 (Amended). A compound as claimed in Claim 1, wherein R^1 represents optionally substituted - $(CH_2)_a$ -phenyl, in which a is 0, 1, 2 or 3, or optionally substituted, optionally unsaturated, linear, branched or cyclic, C_{1-18} alkyl (which latter group may also be interrupted by an oxygen atom).

20 (Amended). A method of prophylaxis or treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound as defined in Claim 1 to a person in need thereof.

22 (Amended). A compound of formula II

wherein R², R³, R⁴, R^{5a}, R^{5b}, R⁶, A, B and D are as defined in Claim 1, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then D does not represent H or OH.

23 (Twice amended). A compound of formula IV

$$R^{3}$$
 R^{2} R^{5a} R^{5b} R^{5b} R^{5b} R^{5b} R^{5b}

wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} and X are as defined in Claim 1, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then at least one of R^2 and R^3 represents OR^7 , $OC(O)R^8$ or C_{1-4} alkyl, which alkyl group is substituted with one or more nitro or cyano groups.

24 (Amended). A compound of formula VIII

wherein R^1 , R^4 , R^{5a} , R^{5b} , R^6 A, B, D and X are as defined in Claim 1, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then D does not represent H or OH.

26 (Twice amended). A process for the preparation of a compound of formula VIII, as defined in Claim 24, or a compound of formula XVII, as defined in Claim 25, which comprises reaction of a compound of formula XXIX,

wherein R^Z represents H or -C(O)XR¹ and R¹, R^{5a}, R^{5b} and X are as defined in Claim 1 with a compound of formula XXX,

or a protected derivative thereof, wherein R⁴, R⁶, A, B and D are as defined in Claim 1, in the presence of a formaldehyde.